Biomerica (BMRA) Price & Analysis

Compare

406 Followers

BMRA Stock Chart & Stats

$2.65

-$0.02(-5.81%)

At close: Jan 08 4:00 PM EST

$2.65

-$0.02(-5.81%)

Day’s Range― - ―

52-Week Range$2.08 - $10.16

Previous CloseN/A

Volume74.49K

Average Volume (3M)190.48K

Market Cap

$7.81M

Enterprise Value$5.58M

Total Cash (Recent Filing)$3.05M

Total Debt (Recent Filing)$373.00K

Price to Earnings (P/E)―

Beta2.11

Next Earnings

Jan 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding2,947,966

10 Day Avg. Volume453,881

30 Day Avg. Volume190,481

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.71

Price to Sales (P/S)1.32

P/FCF Ratio-1.81

Enterprise Value/Market Cap0.71

Enterprise Value/Revenue1.14

Enterprise Value/Gross Profit8.77

Enterprise Value/Ebitda-1.61

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Biomerica News

Biomerica announces CMS Medicare payment rate of $300 for IBS test

Biomerica (BMRA) announced that the Centers for Medicare & Medicaid Services, CMS, has issued its final pricing determination...

4d ago

BMRA

Two new option listings and eighteen option delistings on December 22nd

New option listings for December 22nd include High Templar Tech Limited (HTT) and Irobot Corporation (IRBTQ). Option delistings...

5d ago

EPS

Biomerica’s complete screening test portfolio authorized in Egypt

Biomerica (BMRA) announced today that the Egyptian Drug Authority has granted authorization for Biomerica’s complete portfolio of rapid...

16d ago

BMRA

Biomerica Stockholders Approve Key Proposals at Annual Meeting

Biomerica ( ($BMRA) ) has issued an update. Biomerica, Inc. held its 2025 Annual Meeting of Stockholders on...

11d ago

BMRA

Biomerica announces inFoods IBS product featured in Biotherapeutics Quarterly

Biomerica (BMRA) announced that its inFoods IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue...

1M ago

BMRA

Biomerica expands CDMO services to meet growing market demand

Biomerica (BMRA) announced the expansion of its Contract Development and Manufacturing Organization, CDMO, services to meet accelerating market...

2M ago

BMRA

Biomerica, Henry Schein enter marketing services agreement for inFoods IBS test

Biomerica (BMRA) announced today a marketing services arrangement with Henry Schein (HSIC) to market Biomerica’s inFoods Irritable Bowel...

2M ago

BMRA

HSIC

Biomerica reports Q1 EPS 0c vs. (8c) last year

Reports Q1 revenue $1.4M vs. $1.8M last year. Published first on TheFly – the ultimate source for real-time,...

2M ago

BMRA

Biomerica Appoints Gary Huff to Board of Directors

Biomerica ( ($BMRA) ) just unveiled an announcement. On October 7, 2025, Biomerica, Inc. announced the appointment of...

3M ago

BMRA

Biomerica appoints Gary Huff to board of directors

Biomerica (BMRA)announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr....

3M ago

BMRA

Biomerica announces launch of inFoods IBS Trigger Food Navigator

Biomerica (BMRA) announced the launch of its inFoods IBS Trigger Food Navigator, an AI-backed digital companion tool designed...

4M ago

BMRA

Biomerica announces UAE Ministry of Health approved its Fortel Kidney Test

Biomerica (BMRA) announced that the United Arab Emirates, UAE, Ministry of Health and Prevention has approved its Fortel...

4M ago

BMRA

Biomerica Inc. Navigates Trade Challenges: Impact on Revenue and Supply Chain

Biomerica Inc (BMRA) has disclosed a new risk, in the Capital Markets category. Biomerica Inc. faces potential business...

4M ago

BMRA

Biomerica Appoints Eric B. Chin to Board

Biomerica ( ($BMRA) ) has issued an update. On June 4, 2025, Cathy Coste resigned from Biomerica‘s Board...

7M ago

BMRA

BMRA FAQ

What was Biomerica Inc’s price range in the past 12 months?

Biomerica Inc lowest stock price was $2.08 and its highest was $10.16 in the past 12 months.

What is Biomerica Inc’s market cap?

Biomerica Inc’s market cap is $7.81M.

When is Biomerica Inc’s upcoming earnings report date?

Biomerica Inc’s upcoming earnings report date is Jan 21, 2026 which is in 25 days.

How were Biomerica Inc’s earnings last quarter?

Biomerica Inc released its earnings results on Oct 15, 2025. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.

Is Biomerica Inc overvalued?

According to Wall Street analysts Biomerica Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biomerica Inc pay dividends?

Biomerica Inc does not currently pay dividends.

What is Biomerica Inc’s EPS estimate?

Biomerica Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biomerica Inc have?

Biomerica Inc has 2,947,966 shares outstanding.

What happened to Biomerica Inc’s price movement after its last earnings report?

Biomerica Inc reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.694%.

Which hedge fund is a major shareholder of Biomerica Inc?

Currently, no hedge funds are holding shares in BMRA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biomerica Inc

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.